Xos (XOS) Director Alice Yake Sells Shares

What Happened

• Director Alice Yake sold a total of 7,500 Xos (XOS) shares in three open‑market transactions on July 10, 13 and 14, 2026 for aggregate cash proceeds of approximately $18,087 (individual sales: 2,500 @ $2.49 = $6,229; 2,500 @ $2.35 = $5,871; 2,500 @ $2.39 = $5,987).
• On July 10, 2026 she was also granted 62,876 Restricted Stock Units (RSUs): 2,292 RSUs that vested immediately (issued in lieu of cash retainer) and 60,584 RSUs that are unvested and vest on the earlier of the first anniversary of the grant or the day before the 2027 annual meeting, subject to continued service.
• The sales were executed under a Rule 10b5‑1 trading plan. This filing is an amendment (filed 2026‑08‑27) to correct transaction codes for the sales; no other information was changed.

Key Details

• Transaction dates & prices: 7/10/2026 — 2,500 @ $2.49; 7/13/2026 — 2,500 @ $2.35; 7/14/2026 — 2,500 @ $2.39.
• Aggregate proceeds from sales: ≈ $18,087.
• RSUs granted 7/10/2026: total 62,876 (2,292 vested immediately; 60,584 unvested and subject to future vesting conditions). RSUs represent contingent rights to receive one share upon settlement.
• Sales executed pursuant to a 10b5‑1 plan adopted by the reporting person on Sept 29, 2025.
• Shares owned after the transactions are not specified in this Form 4.
• Amendment note: Form 4 was amended to change the disposition transaction codes from 'D' to 'S' to reflect open‑market sales; no other changes were made.

Context

• RSU grants are awards that convert to shares upon vesting; the 2,292 RSUs vested immediately and thus are not contingent.
• Trades under a 10b5‑1 plan are pre‑planned and typically indicate scheduled selling rather than ad hoc decisions; they do not by themselves indicate insider sentiment.
• This report records sales (not purchases), which are common for non‑employee directors receiving equity compensation and may reflect routine portfolio management or cash needs rather than a view on company prospects.